share_log

Chardan Capital Maintains Buy on Axcella Health, Lowers Price Target to $5

Benzinga Real-time News ·  Nov 2, 2022 10:36

Chardan Capital analyst Keay Nakae maintains Axcella Health (NASDAQ:AXLA) with a Buy and lowers the price target from $7 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment